Tesla’s Optimus humanoid robot moves from prototype to 20k units per week, sparking debate on its real‑world use in security, factory tasks, and AI‑driven labor.
Explore how unverified claims of cellular rejuvenation, like epitalon’s 60‑year reversal, are driving biotech volatility, market speculation, and future longevity prospects.
How AI competition is reshaping global capital flows, driving 90% of investment into tech, and impacting geopolitics, commerce, and Gen‑Z’s social choices.